G
Genetic Archaeology
GENETIC ARCHAEOLOGY // PROFILE

LPA

Lipoprotein(a) / Apolipoprotein(a)

CHR 6
6q25.3-q26

Overview

Few lipids in preventive cardiology are as strictly genetically programmed as Lipoprotein(a) [Lp(a)]. While LDL cholesterol responds strongly to diet and weight, more than 90 percent of blood Lp(a) concentration is fixed at birth by Kringle repeat length and tag SNPs inside the LPA gene.

Roughly one in five adults carries elevated Lp(a) without knowing it, because standard lipid panels do not report it unless ordered specifically—yet cardiovascular genetics identifies Lp(a) as a potent independent driver of atherosclerosis and calcific aortic valve stenosis.

📍 Position
6q25.3-q26 (Chromosome 6)
🏷️ Category
Metabolism & Cardiovascular
🧪 Function
Apolipoprotein(a) Structural Gene
📊 Influence
Genetically fixed Lp(a) & heart risk

Function of LPA

Structurally, Lp(a) resembles an LDL cholesterol particle carrying an extra sticky coiled protein ribbon—apolipoprotein(a)—whose structure mimics plasminogen, promoting oxidized phospholipid trapping in arterial plaques and interfering gently with clot lysis.

Key Aspects:

🧬 Kringle Repeats & Tag SNPs

Fewer Kringle IV type 2 repeats let the liver secrete Apo(a) much faster, skyrocketing plasma Lp(a). Variants rs10455872 (G) and rs3798220 (C) reliably flag small, high-output alleles.

❤️ Aggressive Overall Risk Control

Even though diet and statins barely lower Lp(a) itself, lowering total ApoB/LDL cholesterol, blood pressure, and blood sugar drastically shrinks lifetime plaque risk.

💡 Once-in-a-Lifetime Blood Test: European (ESC/EAS) and AHA/ACC guidelines endorse measuring blood Lp(a) directly at least once in every adult—and emerging RNA-silencing therapies (pelacarsen, olpasiran) are currently in late Phase 3 trials.

🧬 Genetic Variants (SNPs)

Two landmark NEJM-validated SNPs account for a major share of severe genetic Lp(a) elevation:

rs10455872
6:160589086
Low Lp(a)

A
/
High Lp(a)

G
LPA Intronic Risk Variant
G carriers typically exhibit 3- to 5-fold higher median Lp(a) blood concentrations and ~1.5x higher coronary disease odds.
G allele frequency:
~7-8% (Europe)
rs3798220
6:160540105
Reference

T
/
High Lp(a)

C
LPA Ile4399Met
Protease-like domain substitution tightly tagging elevated small-isoform Lp(a) particles and earlier myocardial infarction onset.
C allele frequency:
~2% (Europe)

Practical Significance

✅ Strategies & Guidance

  • Order a Blood Lp(a) Test: Preferably in nmol/L (risk climbs above 75–125 nmol/L / 30–50 mg/dL); DNA SNPs never replace direct blood measurement.
  • Drive Down ApoB & LDL-C: Because Lp(a) cannot yet be lowered easily with diet, optimizing overall ApoB via Mediterranean nutrition and clinician-guided LDL lowering (e.g., PCSK9/statins) shrinks cumulative arterial hazard.
  • Optimize Vascular Hygiene: Zero smoking, tight blood pressure control (<120/80 mmHg), regular aerobic exercise, and blood-sugar stewardship.

⚠️ Clinical Notes & Risks

  • Silent Premature Plaque: Elevated Lp(a) explains many unexpected early heart attacks despite apparently ‘normal’ standard LDL numbers.
  • Calcific Aortic Valve Disease: Carried oxidized phospholipids accelerate aortic valve stiffening—echocardiographic follow-up matters when levels run high.
  • Familial Screening: When elevated Lp(a) (>50 mg/dL) is found, first-degree relatives carry a 50% chance of sharing it.
🩺 Medical Disclaimer: Genetic test results for LPA (Lipoprotein(a)) should always be interpreted alongside laboratory biomarkers, medications, and qualified medical or genetic counseling.

📚 Data Sources

  • OMIM: #152200 (Lipoprotein(a) / Apolipoprotein(a))
  • dbSNP: rs10455872, rs3798220
  • ESC/EAS Dyslipidaemia Guidelines: Universal Adult Lp(a) Testing Recommendation
  • NEJM (Clarke et al.): Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

Last Update: November 2026

Related Research Guides for LPA

Related Genes in Metabolism